Introduction
Potassium is the most abundant cation in the body.
Although extracellular potassium accounts for only 2% of total body potassium, it has a major effect on the ratio of intracellular to extracellular potassium and on the resting membrane potential. As a result, serum potassium is normally regulated around the narrow range of 3. Hypokalemia is a common clinical problem. The kidney is responsible for long term potassium homoeostasis, as well as the serum potassium concentration. The main nephron site where K secretion is regulated is the cortical collecting duct, mainly via the effects of aldosterone. Aldosterone interacts with the mineralocorticoid receptor to increase sodium reabsorption and potassium secretion; the removal of cationic sodium makes the lumen relatively electronegative, thereby promoting passive potassium secretion from the tubular cell into the lumen through apical potassium channels. As a result, any condition that decreases the activity of renal potassium channels results in hyperkalemia (for example, amiloride intake or aldosterone deficiency) whereas their increased activity results in hypokalemia (for example, primary aldosteronism or Liddle's syndrome). The cause of hypokalemia can usually be determined from the history. If there is no apparent cause, the initial step is to see if hypokalemia is in associated with systemic hypertension or not. In the former group hypokalaemia is associated with a high mineralocorticoid effect or hyperactive sodium channel as in Liddle's syndrome.
In hypertensive hypokalemic patients, measurement of the renin, aldosterone, and cortisol concentrations would be of help in differential diagnosis.
Hypokalemia, Hyperaldosteronism, Hypertension, Liddle's syndrome Review article reabsorption and potassium secretion; the removal of cationic sodium makes the lumen relatively electronegative, thereby promoting passive potassium secretion from the tubular cell into the lumen through apical potassium channels (Fig. 1) . As a result, any condition that decreases the activity of renal potassium channels results in hyperkalemia (for example, amiloride intake or aldosterone deficiency) whereas their increased activity results in hypokalemia (for example, primary aldosteronism or Liddle's syndrome) 1, 2) . Increased aldosterone, in addition, can cause metabolic alkalosis by increasing bicarbonate reabsorption in the collecting duct.
The cause of hypokalemia can usually be determined from the history. If there is no apparent cause, the initial step is to see if hypokalaemia is in association with systemic hypertension or not. In the former group hypokalaemia is associated with a high mineralocorticoid effect or hyperactive sodium channel as in Liddle's syndrome. In normotensive patients, hypokalaemia could be secondary to overt or occult gastrointestinal loss or due to renal potassium wasting (Table 1) . In hypertensive hypokalemic patients, measurement of the renin, aldosterone, and cortisol concentrations would be of help in differential diagnosis.
This review discusses the biology of aldosterone and cortisol followed by a discussion of several forms of hypertensive hypokalemic disorder.
Aldosterone and cortisol synthesis
Aldosterone is synthesized in the zona glomerulosa of the adrenal cortex. In the zona glomerulosa progesterone is hydroxylated at C21 by CYP21A2 to yield The last step in cortisol biosynthesis is the 11-beta-hydroxylation of 11-deoxycortisol, a reaction catalyzed by the mitochondrial enzyme CYP11B1.
CYP11B1 is also encoded by a gene on chromosome 8q24.3, near the gene CYP11B2. The product of the CYP11B1 gene is a 51 kDa protein that is nearly identical to the CYP11B2 enzyme responsible for the terminal steps of aldosterone synthesis, except that it lacks the ability to convert corticosterone to aldosterone ( Fig. 2) 3)
.
Cortisol metabolism
Circulating concentrations of cortisol are 100-1000-fold higher than those of aldosterone. Furthermore, cortisol has a high affinity for the MR. However, . 
Primary aldosteronism (PA)
Mineralocorticoid hypertension is a potentially reversible cause of hypertension that is characterized by the triad of hypertension, metabolic alkalosis, and hypokalemia (Table 2 ) 5, 6) .
PA is the most common form of mineralocorticoid hypertension. The prevalence has varied from 0.5% to 10% of hypertensive patients. The two major subtypes are bilateral adrenal hyperplasia and adrenal adenoma.
Familial forms of PA include familial hyperaldosteronism type 1 (FH-1) or glucocorticoid-remediable aldosteronism (GRA), and FH-2 (familial occurrence of bilateral adrenal hyperplasia, adrenal adenoma or both).
Screening for PA is a challenging topic. An important point is that not all patients with PA present has also been introduced as a potential confirmatory technique for primary aldosteronism. Because the CST did not depend on sodium intake, it could be performed in patients for whom salt loading is contraindicated (such as those with cardiac failure) and is an efficient alternative test 7) . . An important clinical feature associated with GRA is early hemorrhagic stroke and ruptured aneurysm, occurring at a mean age of 32 years and associated with high mortality (61%).
As a result, screening with magnetic resonance imaging angiography, beginning at puberty and then every five years, has been recommended to detect asymptomatic intra-cranial aneurysms. A confirmatory diagnosis can be made with either a dexamethasone-suppression test, measurement urinary 18/hydroxyl/oxy steroids, or direct genetic testing. In GRA the zona fasciculata ectopically produces aldosterone under the regulation of ACTH.
As a result, when 0.5 mg of dexamethasone is given every 6 hours for two days, suppression of aldosterone to undetectable levels (<4ng/dL) is seen in GRA subjects 10) . GRA patients excrete large amounts of urinary 18-hydroxycortisol and 18-oxocortisol . In its full expression AME is rare, with fewer than 100 cases reported worldwide, but presentation is dramatic. Usually patients are children with Thus, a high urinary free cortisol (UFF) to urinary free cortisone (UFE) ratio will be diagnostic, as it only reflects 11 -HSD2 activity in the kidney, but not 11 β β -HSD1 activity in the liver 14, 15) . DNA analysis is required to confirm the diagnosis. .
Ectopic ACTH Syndrome
Cushing s syndrome can also present signs with ' signs and symptoms of mineralocorticoid excess, particularly in the sub-group caused by ectopic ACTH production. The ectopic ACTH syndrome is characterized by mineralocorticoid excess, with hypokalemic alkalosis found in 95-100% of cases, in contrast to <10% in other forms of Cushing's syndrome.
ACTH has no direct effect on 11 -HSD2, but the β enzyme is saturated in ectopic ACTH syndrome by very high concentrations of ACTH-dependent 11 -HSD β substrates such as cortisol and corticosterone. Both the urinary ratio of THF+allo-THF/THE and UFF/UFE are elevated, not because of impaired 11 -HSD2 activity, β but because of substrate saturation 17) .
Liddle syndrome
Liddle syndrome is a rare form of an autosomaldominant disorder. This syndrome results from constitutive activation of the epithelial Na channel (ENaC), resulting in sodium retention and urinary potassium and hydrogen ion wasting, causing hypokalaemic alkalosis with early onset severe hypertension and suppressed renin and aldosterone (due to low renin plus hypokalaemia) 18) .
The amiloride-sensitive ENaC is comprised of three subunit proteins ( , and ) having short cytosolic α β γ termini, 2 transmembrane domains, and a large extracellular loop. The subunit appears to be re α -quired for the assembly or function of the whole complex. Liddle syndrome is caused by missense or frameshift mutations that delete or disrupt a prolinerich motif (PPPxY) in the intracytoplasmic C-terminal tails of the or subunits. These muta ' ' β γ tions increase expression of the ENaC at the cell surface by disrupting its binding to Nedd4-2, a ubiquitin-protein ligase that targets the ENaC for degradation 19) .
The condition should be suspected in patients (es- 
Conclusion
The presence of mineralocorticoid excess should be suspected in any patient with the triad of hypertension, unexplained hypokalemia, and metabolic alkalosis.
Avoiding hypokalemia is beneficial in several cardiovascular disease states including acute myocardial infarction, heart failure, and hypertension. In hypertensive patients, it seems beneficial to aim for serum potassium levels 3.5 to 5.0 mEq/L. All pharmacologically managed patients with mineralocorticoid excess should receive a mineralocorticoid receptor antagonist to prevent the negative effects of aldosterone on nonepithelial tissues
